Stoke Therapeutics announced the appointment of Thomas Leggett as CFO. In this role, Leggett will be responsible for overseeing all aspects of the company’s financial strategy and operations. Leggett succeeds Stephen Tulipano, who resigned his position as Stoke’s CFO effective Tuesday, May 7. Leggett brings more than 20 years of experience as a biotechnology executive, board member and as an investment banker. Prior to joining Stoke, Leggett served as CFO at Affinia Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer
- Stoke Stock (NASDAQ:STOK) Gains on Drug Update; Is There More Upside Left?
- Stoke Therapeutics Launches Public Offering for Clinical Development
- Biotech Alert: Searches spiking for these stocks today
- Stoke Therapeutics 5.556M share Secondary priced at $13.50